Featured Clinical Trials

Patients who are interested need to go to our prescreening portal and finish a one-minute questionnaire.

This is a phase III, randomized, open-label study of HLX10 plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus Chemotherapy.

Who can participate?

1. A patient has been newly diagnosed with extensive-stage small cell lung cancer. A patient has full mobility even with current symptoms.
2. A patient has not yet received treatment for extensive-stage small cell lung cancer OR if you were previously diagnosed with limited-stage small cell lung cancer, your last treatment was at least 6 months ago.
3. A patient does not have any other active malignancies and you have not had a history of malignancy within the last 5 years.
4. You may also answer YES if you have been cured for basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ.
5. A patient does not have HIV, Hepatitis B or Hepatitis C.
6. A patient does not have known or active brain metastasis and/or carcinomatous meningitis.

PMV Pharma Clinical Study Information Center
(609) 235-4038, clinicaltrials@pmvpharma.com

Mutations in the p53 gene (TP53) can disrupt the body’s ability to prevent cancer. PC14586 is designed to fix a specific mutation (Y220C) in the p53 protein, restoring its ability to prevent tumors from growing. The primary objective of the PYNNACLE Phase 1 trial is to  establish the maximum tolerated dose and the recommended orally administered dose of PC14586. The primary objective of the PYNNACLE Phase 2 is to assess the efficacy and safety of PC14586 in participants with advanced solid tumors harboring a TP53 Y220C mutation.

Participants would be considered eligible for the PYNNACLE study, if the following criteria apply:

• At least 18 years of age or 12 to 17 years of age after adequate adult safety data become available
• Advanced solid malignancy with a TP53 Y220C mutation
• Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
• Previously treated with one or more lines of anticancer therapy and progressive disease
• Adequate organ function

Gerrica Frankfurth, EBMClinical@endeavorbiomedicines.com
858-727-3199

PTCH-1 is a tumor suppressor gene/ protein in the Sonic Hedgehog pathway. The study drug, ENV-101, acts on a protein that is thought to be involved with the growth of these abnormal cells caused by a mutation of the PTCH-1 gene. By blocking this process, ENV-101 may slow the progress of the disease and may result in a partial or complete response. This is an oral once a day tablet.

Key eligibility criteria:

• Females or males greater than or equal to 18 years of age. Females and males between 12 and 17 years of age (inclusive) may be enrolled if deemed appropriate after review of an X-ray with the sponsor for evaluation of growth plate development
• Has histologically or cytologically confirmed solid tumor that harbors a PTCH1 loss of function mutation, identified via genomic sequencing routinely performed at a CLIA certified laboratory
• Able to take medication orally
• Patients must be refractory to all standard of care therapy, or standard or curative therapy does not exist, or the patient has documented their refusal of standard of care therapies
• Patients willing to sign and have a full understanding of the informed consent form
• Life expectancy of ≥ 3 months

ABBVIE CALL CENTER, 844-663-3742; abbvieclinicaltrials@abbvie.com

A multicohort, multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399, an Antibody Drug Conjugate, in Participants With Advanced Solid Tumors

Currently open for enrollment:

• Monotherapy Expansion Cohort for locally advanced or metastatic, non-squamous, EGFR wild type, c-Met overexpressed (per IHC testing) NSCLC.
• Combination therapy Arm E (Telisotuzumab vedotin plus Osimertinib), for metastatic/locally advanced nonsquamous NSCLC with documented Epidermal Growth Factor Receptor (EGFR) mutation(s) del19 or L858R and c-MET overexpressed (per IHC testing)

ABBVIE CALL CENTER, 844-663-3742; abbvieclinicaltrials@abbvie.com

Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated.  Participants must have c-Met overexpressing NSCLC (determined by immunohistochemistry), must have histologically documented non-squamous NSCLC that is locally advanced or metastatic, must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, and must not have an actionable EGFR activating mutation.

ABBVIE CALL CENTER, 844-663-3742; abbvieclinicaltrials@abbvie.com

Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin. Stage 1 is complete. Stage 2 is enrolling participants with non-squamous EGFR wild-type NSCLC. Participants must also have locally advanced or metastatic NSCLC that is c-Met overexpressed (determined by immunohistochemistry), and must have received no more than 2 lines of prior systemic therapy in the locally advanced/metastatic setting.